Lenalidomide vs. Placebo for Multiple Myeloma Patients Following a Single ASCT
Sarah Holstein, MD, PhD, assistant professor of oncology, Roswell Park Cancer Institute, discusses a randomized study that compared lenalidomide with placebo for patients with multiple myeloma, following a single autologous stem cell transplant (ASCT).
In the updated analysis, the current median follow up for overall survival (OS) was 65 months. When it was previously published, the OS was 34 months. The longer follow up has shown a significant improvement in time to progression for lenalidomide vs placebo.
The patients on the lenalidomide arm have not yet reached a median OS; these patients continue to do very well.
Sarah Holstein, MD, PhD, assistant professor of oncology, Roswell Park Cancer Institute, discusses a randomized study that compared lenalidomide with placebo for patients with multiple myeloma, following a single autologous stem cell transplant (ASCT).
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More
